الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 254 |  |  |
| | | from | 254 | | |
Abstract
The Study Is A Prospective Randomized Phase III Clinical Study Included 62 Patients With Locally Advanced Rectal Carcinoma Were Included In The Study, Treated By Cnoncurrent Chemo-Radiation Followed By Surgery, Randomized Into 2 Arms: Arm I (31 Patients) Received Radiotherapy 45Gy/5W And 5-FU (IV Bolus Of 325mg/M2/Day For 5days), The First And Last Weeks Of Radiotherapy And Arm II (31 Patients) Received Same Regimen And Cisplatin 6mg/M2(Maximum 10 Mg) Daily,15-30 Minutes Before Radiation.The Study Concluded That: There Were No Statistical Significant Differences Between 2 Arms Regarding LC, DFS And OS. Arm II Was Better Regarding Operability Rate, Sphincter Saving Procedure And Functional Preservation Tumor Down Staging, Tumor Regression 50%, Histological Tumor Cell Necrosis, Complete Pathological Response.Both Regimens Were Comparable As Regards Toxicity Profile. Bcl-2 Was The Only Biological Marker Proved To Have A Prognostic Value In DFS For The Whole Studied Group, And LC And DFS In Arm II.